Terms: = Breast cancer AND PTK6, BRK, 5753, ENSG00000101213, Q13882, FLJ42088 AND Treatment
25 results:
1. Prognostic impact of ptk6 expression in triple negative breast cancer.
Chen Y; Qu W; Tu J; Yang L; Gui X
BMC Womens Health; 2023 Nov; 23(1):575. PubMed ID: 37932734
[TBL] [Abstract] [Full Text] [Related]
2. Comprehensive Analysis Reveals ptk6 as a Prognostic Biomarker Involved in the Immunosuppressive Microenvironment in breast cancer.
Wang L; Luo S; Wang Z; Huang Y; Luo Y; Xie X
J Immunol Res; 2022; 2022():5160705. PubMed ID: 36405012
[TBL] [Abstract] [Full Text] [Related]
3. breast Tumour Kinase (brk/ptk6) Contributes to breast Tumour Xenograft Growth and Modulates Chemotherapeutic Responses In Vitro.
Burmi RS; Box GM; Wazir U; Hussain HA; Davies JA; Court WJ; Eccles SA; Jiang WG; Mokbel K; Harvey AJ
Genes (Basel); 2022 Feb; 13(3):. PubMed ID: 35327957
[TBL] [Abstract] [Full Text] [Related]
4. A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis.
Brufsky A; Kim SB; Zvirbule Ž; Eniu A; Mebis J; Sohn JH; Wongchenko M; Chohan S; Amin R; Yan Y; McNally V; Miles D; Loi S
Ann Oncol; 2021 May; 32(5):652-660. PubMed ID: 33539944
[TBL] [Abstract] [Full Text] [Related]
5. Strategic Developments & Future Perspective on Gene Therapy for breast cancer: Role of mTOR and brk/ ptk6 as Molecular Targets.
Sahu R; Pattanayak SP
Curr Gene Ther; 2020; 20(4):237-258. PubMed ID: 32807051
[TBL] [Abstract] [Full Text] [Related]
6. Genomic landscape of metastatic breast cancer identifies preferentially dysregulated pathways and targets.
Paul MR; Pan TC; Pant DK; Shih NN; Chen Y; Harvey KL; Solomon A; Lieberman D; Morrissette JJ; Soucier-Ernst D; Goodman NG; Stavropoulos SW; Maxwell KN; Clark C; Belka GK; Feldman M; DeMichele A; Chodosh LA
J Clin Invest; 2020 Aug; 130(8):4252-4265. PubMed ID: 32657779
[TBL] [Abstract] [Full Text] [Related]
7. brk phosphorylates SMAD4 for proteasomal degradation and inhibits tumor suppressor FRK to control SNAIL, SLUG, and metastatic potential.
Miah S; Banks CAS; Ogunbolude Y; Bagu ET; Berg JM; Saraf A; Tettey TT; Hattem G; Dayebgadoh G; Kempf CG; Sardiu M; Napper S; Florens L; Lukong KE; Washburn MP
Sci Adv; 2019 Oct; 5(10):eaaw3113. PubMed ID: 31681835
[TBL] [Abstract] [Full Text] [Related]
8. Taxol Induces brk-dependent Prosurvival Phenotypes in TNBC Cells through an AhR/GR/HIF-driven Signaling Axis.
Regan Anderson TM; Ma S; Perez Kerkvliet C; Peng Y; Helle TM; Krutilina RI; Raj GV; Cidlowski JA; Ostrander JH; Schwertfeger KL; Seagroves TN; Lange CA
Mol Cancer Res; 2018 Nov; 16(11):1761-1772. PubMed ID: 29991529
[TBL] [Abstract] [Full Text] [Related]
9. 13
Souid S; Elsayed HE; Ebrahim HY; Mohyeldin MM; Siddique AB; Karoui H; El Sayed KA; Essafi-Benkhadir K
Mol Carcinog; 2018 Nov; 57(11):1507-1524. PubMed ID: 29978911
[TBL] [Abstract] [Full Text] [Related]
10. Small molecule inhibitors reveal ptk6 kinase is not an oncogenic driver in breast cancers.
Qiu L; Levine K; Gajiwala KS; Cronin CN; Nagata A; Johnson E; Kraus M; Tatlock J; Kania R; Foley T; Sun S
PLoS One; 2018; 13(6):e0198374. PubMed ID: 29879184
[TBL] [Abstract] [Full Text] [Related]
11. Repression of Fyn-related kinase in breast cancer cells is associated with promoter site-specific CpG methylation.
Bagu ET; Miah S; Dai C; Spriggs T; Ogunbolude Y; Beaton E; Sanders M; Goel RK; Bonham K; Lukong KE
Oncotarget; 2017 Feb; 8(7):11442-11459. PubMed ID: 28077797
[TBL] [Abstract] [Full Text] [Related]
12. ptk6 Inhibition Suppresses Metastases of Triple-Negative breast cancer via SNAIL-Dependent E-Cadherin Regulation.
Ito K; Park SH; Nayak A; Byerly JH; Irie HY
Cancer Res; 2016 Aug; 76(15):4406-17. PubMed ID: 27302163
[TBL] [Abstract] [Full Text] [Related]
13. A bioinformatics approach for precision medicine off-label drug drug selection among triple negative breast cancer patients.
Cheng L; Schneider BP; Li L
J Am Med Inform Assoc; 2016 Jul; 23(4):741-9. PubMed ID: 27107440
[TBL] [Abstract] [Full Text] [Related]
14. Protein tyrosine kinase 6 promotes ERBB2-induced mammary gland tumorigenesis in the mouse.
Peng M; Ball-Kell SM; Tyner AL
Cell Death Dis; 2015 Aug; 6(8):e1848. PubMed ID: 26247733
[TBL] [Abstract] [Full Text] [Related]
15. ptk6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
[TBL] [Abstract] [Full Text] [Related]
16. Protein Tyrosine Kinase 6 Regulates UVB-Induced Signaling and Tumorigenesis in Mouse Skin.
Chastkofsky MI; Bie W; Ball-Kell SM; He YY; Tyner AL
J Invest Dermatol; 2015 Oct; 135(10):2492-2501. PubMed ID: 25938342
[TBL] [Abstract] [Full Text] [Related]
17. breast tumor kinase/protein tyrosine kinase 6 (brk/ptk6) activity in normal and neoplastic biliary epithelia.
Mizuguchi Y; Specht S; Isse K; Sasatomi E; Lunz JG; Takizawa T; Demetris AJ
J Hepatol; 2015 Aug; 63(2):399-407. PubMed ID: 25770659
[TBL] [Abstract] [Full Text] [Related]
18. Additive impact of HER2-/ptk6-RNAi on interactions with HER3 or IGF-1R leads to reduced breast cancer progression in vivo.
Falkenberg N; Anastasov N; Höfig I; Bashkueva K; Lindner K; Höfler H; Rosemann M; Aubele M
Mol Oncol; 2015 Jan; 9(1):282-94. PubMed ID: 25241146
[TBL] [Abstract] [Full Text] [Related]
19. The marine-derived sipholenol A-4-O-3',4'-dichlorobenzoate inhibits breast cancer growth and motility in vitro and in vivo through the suppression of brk and FAK signaling.
Akl MR; Foudah AI; Ebrahim HY; Meyer SA; El Sayed KA
Mar Drugs; 2014 Apr; 12(4):2282-304. PubMed ID: 24736807
[TBL] [Abstract] [Full Text] [Related]
20. Discovery of 4-anilino α-carbolines as novel brk inhibitors.
Mahmoud KA; Krug M; Wersig T; Slynko I; Schächtele C; Totzke F; Sippl W; Hilgeroth A
Bioorg Med Chem Lett; 2014 Apr; 24(8):1948-51. PubMed ID: 24650640
[TBL] [Abstract] [Full Text] [Related]
[Next]
